Indevus Gains Sanctura XR Approval

The molecule’s “highly differentiated profile” will set it apart from others in the crowded urinary incontinence space, Indevus tells “The Pink Sheet” DAILY.

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet